Proteus Syndrome Market

Market Overview:

The proteus syndrome market reached a value of US$ 1.2 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1.8 Billion by 2034, exhibiting a growth rate (CAGR) of 3.57% during 2024-2034.

The Proteus syndrome market has been comprehensively analyzed in IMARC's new report titled "Proteus Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Proteus syndrome refers to an extremely rare genetic disorder characterized by overgrowth of skin, bones, muscles, and other tissues. The symptoms of this illness can vary widely among patients, but the most common feature may include asymmetrical overgrowth of limbs, leading to differences in size and length between the left and right sides of the body. Numerous other indications associated with the ailment are facial abnormalities, vascular malformations, intellectual and developmental disabilities, irregular pigmentation of the skin, lung and respiratory issues, etc. The diagnosis of Proteus syndrome is typically based on clinical evaluation and may involve several diagnostic tests to confirm the presence of the illness. The healthcare provider will perform genetic testing to detect mutations in a subset of cells that might be contributing to the underlying disease. Numerous radiological imaging procedures, such as X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), etc., may be used to assess and visualize the overgrowth of bones and soft tissues. In some cases, a tissue biopsy may be conducted to analyze the affected areas and rule out various other health conditions with similar symptoms.

The increasing incidences of genetic mutations that lead to uncontrolled cell growth, resulting in the overgrowth of tissues and organs, are primarily driving the Proteus syndrome market. In addition to this, the inflating utilization of physical and occupational therapies, owing to their various benefits, such as improving mobility, reducing the risk of musculoskeletal problems, and enhancing the ability to perform daily tasks, is also creating a positive outlook for the market. Moreover, the widespread adoption of custom orthotics or assistive devices, which help to distribute pressure more evenly on surrounding tissues, thereby providing pain relief, is further bolstering the market growth. Apart from this, the rising usage of epiphysiodesis techniques to equalize limb lengths and improve the patient's gait and overall functional capacity is acting as another significant growth-inducing factor. Additionally, the emerging popularity of Miransertib therapy, since it works by inhibiting a signal transduction pathway to regulate cell proliferation and reduce the overgrowth of tissues in individuals suffering from the ailment, is expected to drive the Proteus syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Proteus syndrome market in the United States, EU4 (Germany, Spain, Italy, France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Proteus syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Proteus syndrome market in any manner.

Recent Developments:

• In December 2022, the Food and Drug Administration (FDA) hosted a listening session aimed at understanding the unique challenges faced by individuals living with Proteus syndrome and their caregivers. This gathering provided a platform to explore the diverse range of symptoms and manifestations associated with the syndrome, as well as to gain insight into patients' perspectives on potential participation in medical interventions.

Key Highlights:

• The prevalence rate of Proteus syndrome is estimated to be 1/1,000,000 live births, according to reports.
• According to the Orphanet Journal of Rare Disease, the prevalence rate of Proteus syndrome in bullous lung disease is 9.3% to 36%.
• In individuals with Proteus syndrome, areas of overgrowth typically exhibit a growth pattern where they increase by 15% in size at one year of age, followed by a 30% increase at three years, and ultimately doubling in size by the age of six.
• Proteus syndrome arises due to a somatic gain-of-function mutation in the AKT1 gene, occurring in less than one out of every million individuals.

Drugs:

Miransertib, alternatively labelled as ARQ 092, is a therapeutic agent targeting the aberrant elevation of phosphorylation in the protein kinase Akt observed in cells and tissues bearing the AKT1 E17K mutation associated with Proteus syndrome. The drug received orphan drug designation from the European Commission in the year 2018.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Proteus syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Proteus syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Proteus syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance 
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Proteus syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Proteus syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Proteus syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Proteus syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Proteus syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Proteus syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Proteus syndrome across the seven major markets?
• What is the size of the Proteus syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Proteus syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Proteus Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Proteus syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Proteus syndrome market?
• What are the key regulatory events related to the Proteus syndrome market?
• What is the structure of clinical trial landscape by status related to the Proteus syndrome market?
• What is the structure of clinical trial landscape by phase related to the Proteus syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Proteus syndrome market?